H.R. 4191 · 119th Congress

MAPS Act

Introduced on Jun 26, 2025 by Doris O. Matsui (D-CA-7). 2 cosponsors, 2 of them from another party. Latest action (Jun 26, 2025): Referred to the House Committee on Energy and Commerce.

Stage
Introduced
Introduced
Jun 26, 2025
Cosponsors
2
2 from the other party
Policy area
Health
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. 2Reported by committee
  3. 3Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

To improve coordination of Federal efforts to identify and mitigate health and national security risks through maintaining a list of essential medicines, conducting a risk assessment of essential medicine supply chains, and creating a monitoring system to map essential medicine supply chains using data analytics.

Subjects

  • Computer security and identity theft
  • Congressional oversight
  • Data collection, sharing, protection
  • Government information and archives
  • Manufacturing
  • Prescription drugs
  • Strategic materials and reserves
  • Supply chain

Summary

By the Congressional Research Service (Introduced in House, Jun 26, 2025). Public domain.

Mapping America’s Pharmaceutical Supply Act or the MAPS Act

This bill requires the Food and Drug Administration (FDA) to continually update its essential medicines list and identify risks and vulnerabilities in the associated supply chains.

In 2020, in response to an executive order, the FDA published a list of essential medicines deemed medically necessary to have available at all times. The bill requires the FDA to update and maintain this list to include drugs and ingredients (1) related to responding to public health threats and emergency incidents, (2) that are of greatest priority for providing health care and are at high risk of shortage, and (3) the shortage of which would adversely affect patients with chronic conditions. The FDA must review the list at least every two years and update it as appropriate.

Also, the bill requires the FDA to conduct a risk assessment of the supply chains for drugs and ingredients on the list and annually report its findings to Congress. The assessment must include information about key manufacturing materials, drugs with primarily foreign or single suppliers, manufacturing capacity, relevant public health and national security risks, and risk mitigation strategies.

Additionally, the Department of Health and Human Services (HHS) must map and monitor relevant supply chains to identify vulnerabilities and provide an annual status report to Congress. HHS must facilitate the secure exchange of information among agencies regarding locations and quantities of production and relevant regulatory actions.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Doris O. MatsuiD-CA-7Sponsor

Republicans · 2

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Jun 26, 2025Introduced in House
  2. Jun 26, 2025Introduced in House
  3. Jun 26, 2025 · HouseReferred to the House Committee on Energy and Commerce.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. ASSOCIATION FOR CLINICAL ONCOLOGY5 reports
    $1.6M reported (all issues)
  2. PHLOW CORP.5 reports
    $770K reported (all issues)Federal contractor: PHLOW CORP.$105.3M in contracts, FY2026AI match · 100%
  3. The United States Pharmacopeial Convention5 reports
    $540K reported (all issues)
  4. VIZIENT, INC.5 reports
    $1.6M reported (all issues)Federal contractor: VIZIENT INC$18.2K in contracts, FY2026AI match · 98%
  5. AMERICAN ASSOCIATION OF ORAL AND MAXILLOFACIAL SURGEONS4 reports
    $300K reported (all issues)
  6. AARP3 reports
    $11.8M reported (all issues)
  7. AMERICAN HOSPITAL ASSOCIATION3 reports
    $18.4M reported (all issues)Federal contractor: AMERICAN HOSPITAL ASSOCIATION$1.2M in contracts, FY2026AI match · 99%
  8. ASSOCIATION FOR ACCESSIBLE MEDICINES2 reports
    $1.8M reported (all issues)

Reports filed in 2025, 2026.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 5, 2026 · loaded Oct 5, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.